Elivaldogene autotemcel approved for treatment of cerebral adrenoleukodystrophy (CALD) in males: A therapeutics bulletin of the American College of Medical Genetics and Genomics (ACMG)

Anna I Scott^{1

2}, Kanwaldeep K Mallhi^{3

4}, Jaya Ganesh⁵, Wei-Liang Chen^{6

7}; ACMG Therapeutics Committee8∗documents@acmg.net

Affiliations

¹ Department of Laboratories, Seattle Children's Hospital, Seattle, WA.
² Department of Laboratory Medicine and Pathology, University of Washington, Seattle, WA.
³ Department of Pediatric Oncology, Roswell Park Comprehensive Cancer Center, Buffalo, NY.
⁴ Department of Pediatrics, State University of New York at Buffalo, Buffalo, NY.
⁵ Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY.
⁶ Department of Genetics, Pediatrics, and Neurology, George Washington University, Washington, DC.
⁷ Center for Neuroscience Research, Children's National Medical Center, Washington, DC.

Anna I Scott et al. Genet Med Open. 2023.

. 2023 Nov 15;1(1):100835.

doi: 10.1016/j.gimo.2023.100835. eCollection 2023.

Anna I Scott^{1

2}, Kanwaldeep K Mallhi^{3

4}, Jaya Ganesh⁵, Wei-Liang Chen^{6

7}; ACMG Therapeutics Committee8∗documents@acmg.net

¹ Department of Laboratories, Seattle Children's Hospital, Seattle, WA.
² Department of Laboratory Medicine and Pathology, University of Washington, Seattle, WA.
³ Department of Pediatric Oncology, Roswell Park Comprehensive Cancer Center, Buffalo, NY.
⁴ Department of Pediatrics, State University of New York at Buffalo, Buffalo, NY.
⁵ Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY.
⁶ Department of Genetics, Pediatrics, and Neurology, George Washington University, Washington, DC.
⁷ Center for Neuroscience Research, Children's National Medical Center, Washington, DC.

No abstract available

Keywords: Cerebral; Elivaldogene; Gene therapy; Newborn screening; X-linked adrenoleukodystrophy.

Conflict of interest statement

The authors declare no conflicts of interest.

1. Huffnagel I.C., Dijkgraaf M.G.W., Janssens G.E., et al. Disease progression in women with X-linked adrenoleukodystrophy is slow. Orphanet J Rare Dis. 2019;14(1):30. doi: 10.1186/s13023-019-1008-6. - DOI - PMC - PubMed
1. Baby’s first test. Conditions—adrenoleukodystrophy. 2022. http://www.babysfirsttest.org/newborn-screening/conditions/adrenoleukody...
1. Regelmann M.O., Kamboj M.K., Miller B.S., et al. Adrenoleukodystrophy: guidance for adrenal surveillance in males identified by newborn screen. J Clin Endocrinol Metab. 2018;103(11):4324–4331. doi: 10.1210/jc.2018-00920. - DOI - PubMed
1. Nieman L.K. Patient education: adrenal insufficiency (beyond the basics). UpToDate. https://www.uptodate.com/contents/adrenal-insufficiency-beyond-the-basics Last Update May 17, 2023.
1. United States Food and Drug Administration Highlights of prescribing information. SKYSONA (elivaldogene autotemcel) suspension for intravenous infusion. https://www.fda.gov/media/161640/download?attachment